The PharmaBlock CMC Lifecycle Strategy Forum held in Nanjing on November 5 and 6 focused on strategic decision-making in drug development, enhancing efficiency and program readiness.

“A development partner needs to understand where a program stands, what the next milestone requires, and how the right expertise and evidence can be brought together to support progress,” said Yaohui Ji, Senior Vice President and Head of CDMO Business at PharmaBlock. Stage-appropriate development, not simply more development A recurring theme throughout the forum was that earlier CMC involvement should not mean moving every late-stage activity to the front of a program. Instead, teams should identify the questions and risks that are critical to the current development stage while maintaining a clear view of future clinical, regulatory, and commercial requirements. In early development, priorities may include candidate developability, API properties, solid form, formulation performance, drug exposure, and fit-for-purpose clinical supply. As programs advance, the focus progressively shifts toward deeper process and product understanding, analytical and control strategies, technology transfer, validation, batch consistency, and reliable commercial supply. Speakers also examined how chemical route and process decisions can affect development timelines, scale-up, manufacturing economics, and future supply. Discussions on model-informed drug development demonstrated how API properties, formulation performance, pharmacokinetics, and exposure-response relationships can be connected to support dose selection and product development decisions. Connecting expertise across the development lifecycle A panel discussion...

PharmaBlock's Green Chemistry Symposium in Zurich gathered industry leaders to discuss sustainable pharmaceutical production amidst climate urgency.

PharmaBlock's recent symposium in Zurich connected industry and academia, promoting innovations in sustainable pharmaceutical practices amidst climate urgency.

PharmaBlock recently convened industry leaders in Zurich to promote green chemistry aimed at sustainable pharmaceutical manufacturing amidst climate challenges.

PharmaBlock's Green Chemistry Symposium in Zurich attracted industry leaders to discuss sustainable practices in pharmaceutical manufacturing amid climate challenges.

Gathering global leaders in Zurich, PharmaBlock's symposium on green chemistry aims to revolutionize sustainable pharmaceutical manufacturing amidst urgent climate challenges.

PharmaBlock Sciences has announced the launch of its first pilot-scale GMP plant in Zhejiang, enhancing its peptide production capabilities and supporting innovative drug development.

PharmaBlock has officially launched Workshop 503 at its Zhejiang facility, enhancing production capacity and implementing sustainable practices for superior pharmaceutical manufacturing.

ZURICH,/PRNewswire/ -- Alors que l'Europe a connu l'un des mois de juin les plus chauds jamais enregistrés, avec des vagues de chaleur prolongées qui ont renforcé l'urgence climatique, des dirigeants de l'industrie pharmaceutique et du monde universitaire se sont réunis à Zurich à...

- PharmaBlock reúne a líderes mundiales de la industria en Zúrich para impulsar la química verde en la fabricación farmacéutica sostenible ZÚRICH, 20 de julio de 2026 /PRNewswire/ -- Mientras Europa experimentaba uno de los junios más calurosos de su historia, con olas de calor...

ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for the PharmaBlock's 3rd Green Chemistry Symposium...

Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide...

NANJING, China, Feb. 18, 2025 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances…